" "
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

GE Healthcare Strengthens R&D Efforts in Alzheimer’s Disease

Published: Friday, April 13, 2012
Last Updated: Friday, April 13, 2012
Bookmark and Share
A Research Collaboration with Clino Ltd., a biotechnology venture from Tohoku University on the development of novel Tau imaging tracers.

Collaboration aims to increase the accuracy of pre-symptomatic diagnoses, and discover pharmaceuticals for PET exams and contributing to new treatments on the molecular level.

GE Healthcare (Chalfont St. Giles, U.K.; John Dineen, president and CEO), Medical Diagnostics business has entered into research collaboration with Clino Ltd. (Sendai, Miyagi Prefecture; Noriaki Satake, president), a venture by Tohoku University to discover in vivo imaging tracers for tau proteins that accumulate in the brains of Alzheimer’s Disease patients.

Yukitsuka Kudo, head of imaging at Clino and a professor at Tohoku University Innovation of New Biomedical Engineering Center, explains the significance of the research project: “The development of radiotracers for tau examinations involves a number of hurdles, and we’re hoping that our joint research with GE’s worldwide operation will enable us to serve as a bridge that will speed the further evolution of these pharmaceuticals, as well as their progression through clinical and therapeutic trials.”

Professor Hiroyuki Arai of the Institute of Development, Aging and Cancer at Tohoku University is the leading domestic researcher on Alzheimer’s and the first person in the world to succeed in detecting tau proteins in cerebrospinal fluid and argue for their significance as surrogate biomarker. Dr. Arai stresses the crucial nature of tau imaging in Alzheimer’s diagnoses: “Research data on PET imaging of amyloid are currently being accumulated, and the thinking now is that if we can conduct additional tau PET imaging on healthy subjects who have tested positive in amyloid PET exams, it will become possible to identify those with high risk of converting to Alzheimer’s. This could lead to diagnoses of pre-clinical stage Alzheimer’s disease’, which may enable prevention before the onset of symptoms.”

As of 2010, there were a total of approximately 35.6 million confirmed cases of Alzheimer’s disease worldwide, and projections indicate that the total will reach 115.4 million cases by 2050.(1) In Japan, which is leading the world in terms of the advance of population aging, there were approximately 2 million cases in 2010, with a projected 3.25 million expected by 2020(2). Alzheimer’s is thought to be caused by accumulations within the brain of beta amyloid and tau proteins. Beta amyloid plaques are thought to begin accumulating within the brain 30 years before symptoms appear, and tau proteins ten years prior.

“The collaboration we are announcing today is part of our ongoing effort to understand and identify Alzheimer’s disease in its very early stages,” said Pascale Witz, CEO of GE Healthcare Medical Diagnostics. “The combination of our different business offerings positions us well to offer an integrated global diagnostics solution for the next generation of therapies. We are working with pharma to understand their strategic needs and design solutions accordingly.”

GE Healthcare already provides the worldwide supply of (11)C-PIB, a PET contrast agent for beta amyloid detection developed by the University of Pittsburgh in 2003 and for which GE Healthcare has obtained exclusive rights of utilization. In addition, if the new joint venture with Clino results in the identification of agents that can distinguish tau accumulation, it will become possible to diagnose the level of severity of Alzheimer’s symptoms. It would also be expected to enable the development of drugs by the pharmaceutical industry and research institutes that would target tau proteins on the molecular level.

Further, GE Healthcare and Clino will consider collaborations with other companies and research institutes developing tau protein therapies. These are among the many efforts aimed at contributing to the early, precise diagnosis and treatment of Alzheimer’s.

In addition to development of pharmaceuticals, GE Healthcare is currently providing diagnostic imaging devices such as PET and magnetic resonance imaging (MRI) scanners in support of the detection of cognitive diseases including Alzheimer’s. They have also been supporters from the outset of the Alzheimer’s Disease Neuroimaging Initiative (ADNI), a clinical observational research project designed to generate standards for Alzheimer’s diagnosis and assessment of the degree to which the disease has progressed. They are moving ahead with a diverse range of efforts toward the imaging evaluation of cognitive diseases around the world including in Japan.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

GE Healthcare to Collaborate with GlaxoSmithKline on Commercial Oncology Testing
The collaboration aims to improve access to diagnostic testing for cancer patients by establishing a network of clinical laboratories to identify genetic mutations associated with different tumour types.
Tuesday, September 30, 2014
GE Acquires Strategic Assets from Thermo
GE to acquire cell culture media and sera, gene modulation and magnetic beads businesses.
Monday, January 06, 2014
GE Healthcare Acquires Unisyn Medical Technologies’ Transactional Business
The proprietary products and services from Unisyn will be integrated into GE Healthcare’s Global Services organization.
Thursday, May 30, 2013
GE Healthcare Completes Acquisition of SeqWright, Inc., Expanding Capabilities in Fast Growing Molecular Diagnostic Segment
Addition of high growth company builds on Clarient’s biopharma service capabilities and provides platform to offer sequencing-based clinical diagnostics in the future.
Thursday, April 05, 2012
GE Healthcare and M+W Group Form Strategic Alliance in Vaccines, Insulin and Biopharmaceuticals
Companies to help emerging nations develop their own manufacturing capabilities for essential biopharmaceuticals, reducing reliance on imports.
Wednesday, December 14, 2011
GE Healthcare to Invest $1 Billion in New Oncology Solutions
Expanding advanced cancer diagnostic and molecular imaging capabilities.
Saturday, September 17, 2011
GE Healthcare Appoints Kieran Murphy as Life Sciences CEO, Successor to Peter Ehrenheim
On 1 April 2011, Kieran Murphy will be promoted to succeed current Life Sciences President and CEO Peter Ehrenheim who will retire from GE after a transition period on July 31 2011.
Tuesday, February 22, 2011
Scientific News
Criminal Justice Alcohol Program Linked to Decreased Mortality
Institute has announced that in the criminal justice alcohol program deaths dropped by 4.2 percent over six years.
Charting Kidney Cancer Metabolism
Changes in cell metabolism are increasingly recognized as an important way tumors develop and progress, yet these changes are hard to measure and interpret. A new tool designed by MSK scientists allows users to identify metabolic changes in kidney cancer tumors that may one day be targets for therapy.
Individuals' Medical Histories Predicted by their Noncoding Genomes
Researchers have found that analyzing mutations in regions of the genome that control genes can predict medical conditions such as hypertension, narcolepsy and heart problems.
'Molecular Movie' Opens Door to New Cancer Treatments
An international team of scientists led by the University of Liverpool has produced a 'structural movie' revealing the step-by-step creation of an important naturally occurring chemical in the body that plays a role in some cancers.
Advancing Synthetic Biology
Living systems rely on a dizzying variety of chemical reactions essential to development and survival. Most of these involve a specialized class of protein molecules — the enzymes.
Preparing for Potential Zika Outbreaks
Experts at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) are developing tools to monitor the spread of the Zika virus and are conducting research to gather more solid data to better assess the risks associated with the infection.
What do Banana Peels and Human Skin Have in Common?
Human skin and banana peels have something in common: they produce the same enzyme when attacked. By studying fruit, researchers have come up with an accurate method for diagnosing the stages of this form of skin cancer.
Biomarker for Recurring HPV-Linked Oropharyngeal Cancers
A look-back analysis of HPV infection antibodies in patients treated for oropharyngeal (mouth and throat) cancers linked to HPV infection suggests at least one of the antibodies could be useful in identifying those at risk for a recurrence of the cancer, say scientists at the Johns Hopkins University.
Counting Cancer-busting Oxygen Molecules
Researchers from the Centre for Nanoscale BioPhotonics (CNBP), an Australian Research Centre of Excellence, have shown that nanoparticles used in combination with X-rays, are a viable method for killing cancer cells deep within the living body.
Genomic Signature Shared by Five Types of Cancer
National Institutes of Health researchers have identified a striking signature in tumor DNA that occurs in five different types of cancer.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!